# Zhengxingu Capital

> Zhengxingu Capital is a VC fund backing Biotechnology, Health Care and Biopharma. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Jul 2022
- Lead investor: 50%
- Last updated: Aug 2026

Zhengxingu Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Health Care | 3 | 38% |
| Biopharma | 1 | 13% |
| Biometrics | 1 | 13% |
| Organic Food | 1 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Series C | 2 | 25% |
| Series B | 1 | 13% |
| Series D | 1 | 13% |
| Venture - Series Unknown | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 6 | 75% |
| United States | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Shanghai Eagtop Electronic Technology | Shanghai Eagtop Electronic Technology is a passive power electronics manufacturer and supplier.EAGTOP is a specialized in researching, developing and manufacturing passive power electronics devices. Our main products include film capacitor, laminated busbar, liquid cooling plates, composite superconducting flat heat pipe, 3D phase change heatsink, reactor, resistor, braking unit, EMC filter and so on. EAGTOP has passed the certification of quality management system ISO9001:2008 and ISO/TS16949-2009.EAGTOP is constantly committed to pioneering and innovating products in its industry, and provides highly competitive and comprehensive solutions to the electronic passive device for worldwide customers. Our products are used in various fields, such as industrial drive, new energy, railway transportation, power quality, etc. In persistent pursuit of fully understanding customers’ demands and putting effort into conducting collaborative R&D together with our customers, we strive to improve the user experience and create value for our customers to the largest extent. |  | Venture - Series Unknown | Jul 03, 2022 |  |
| Frontera Therapeutics | Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market. | $160M | Series B | Jun 24, 2022 |  |
| Alit Life Sciences | Alit positioned as a supplier of instruments, equipment and technical services in the life science and biotechnology industries, the company has developed several series of products from Biotech, Altair, Rigel and Mira after launching its self-developed Countstar IC1000 cell analyzer in 2011. | $14.7M | Series A | May 13, 2022 |  |
| Alit Life Sciences | Alit positioned as a supplier of instruments, equipment and technical services in the life science and biotechnology industries, the company has developed several series of products from Biotech, Altair, Rigel and Mira after launching its self-developed Countstar IC1000 cell analyzer in 2011. | $14.7M | Series A | May 13, 2022 |  |
| ABclonal | ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes. | $189.1M | Series D | Dec 08, 2021 |  |
| Sciwind Biosciences | Sciwind Biosciences is a developers of drugs intended to treat metabolic disorders. The company's drugs contain protein and peptide candidates for non-alcoholic steatohepatitis, enabling physicians to treat their patients in an enhanced way. | $69.8M | Series C | Oct 11, 2021 |  |
| Xiaoxian Dun | Xiaoxian Dun is a healthy food products company. |  | Series C | Mar 31, 2021 |  |
| Zhishan Weixin Biotechnology | Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas. |  | Series A | Feb 09, 2021 |  |

8 of 8 investments shown.

## Co-investors
- [Loyal Valley Capital](https://shizune.co/investors/profile/loyal-valley-capital) — VC Fund, 7 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 2 deals together
- DA Capital — VC Fund, 2 deals together
- Haoyue Capital — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 2 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Zhengxingu Capital invest in?

Zhengxingu Capital invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series C stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Zhengxingu Capital last invest?

The most recent investment recorded for Zhengxingu Capital closed in Jul 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co